PREDICTIVE VALUE OF THE COMBINATION OF SERUM MARKERS, CA125, CASA AND TPS IN OVARIAN-CANCER

被引：20

作者：

DEVINE, PL ^{[1
]}

MCGUCKIN, MA ^{[1
]}

QUIN, RJ ^{[1
]}

WARD, BG ^{[1
]}

机构：

[1] UNIV QUEENSLAND,DEPT OBSTET & GYNAECOL,ST LUCIA,QLD 4067,AUSTRALIA

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 1995年 / 5卷 / 03期

关键词：

CA125; CASA; OVARIAN CANCER; TPS; TUMOR MARKER;

D O I：

10.1046/j.1525-1438.1995.05030170.x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The serum markers CA125, CASA and TPS were compared, with particular reference to the clinical applications of these tumor markers in the management of patients with ovarian cancer (discrimination of benign and malignant disease; indicating prognosis; predicting preclinical recurrence). (i) Using recommended cut-off points, CASA (greater than or equal to 4 U ml(-1)) and TPS (greater than or equal to 80 U l(-1))showed similar sensitivities in ovarian carcinoma (56% and 57% respectively), though these were lower than with CA125 (85% greater than or equal to 35U m l(-1)). The combined use of CA125 with either CASA or TPS at higher cut-off points excluding benign disease (CA125 >345 U ml(-1); CASA >6 U ml(-1); TPS>359 Ul(-1)) improved the discrimination of ovarian cancer from benign adnexal masses (100% positive predictive value with 65% of ovarian cancers detected with CA125-CASA, 61% with CA125-TPS vs 46% with CA125 alone). The combined preoperative use of these markers may therefore assist the general gynecologist in avoiding potentially difficult oncologic surgery. (ii) TPS was the best preoperative indicator of prognosis, possibly due to its association with cell proliferation, while CASA was superior as a postoperative prechemotherapeutic prognostic indicator, possibly due to it being a more accurate indicator of residual disease than the other markers, or the surgeons' assessment. Similarly, CASA gave the best differentiation of patients with minimal residual disease (<1 cm) into those with a good or poor prognosis. (iii) CA125 and CASA each detected preclinical recurrence after surgery and adjuvant therapy in seven of 11 patients (mean lead times 4.6 and 3.1 months respectively) while TPS detected four of these patients (mean lead time 2.4 months). The combined use of CA125 with either assay led to the preclinical detection of eight of 11 patients, with the mean lead time increased to 5.3 months with the CA125-CASA combination.

引用

页码：170 / 178

页数：9

共 28 条

[1]

Mackay E.V., Khoo S.K., Daunter B., Tumor Markers, pp. 405-415, (1992)

[2]

Kenemans P., Bast R.C., Yedema C.A., Price M.R., Hilgers J., CA125 and polymorphic epithelial mucin as serum tumour markers, Cancer Rev, 11-12, pp. 119-144, (1988)

[3]

Jacobs I., Bast R.C., Immunodiagnosis of ovarian tumors, Immunodiagnosis of Cancer, pp. 323-338, (1990)

[4]

Kenemans P., Yedema C.A., Bon G.G., Von Mensdorff-Pouilly S., CA125 in gynaecological pathology — a review, Eurj Obstet Gynecol Reprod Biol, 49, pp. 115-124, (1993)

[5]

Zurawski V.R., Orjaseter H., Ersen A., Jellum E., Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: Relevance for early detection of ovarian cancer, Int J Cancer, 42, pp. 677-680, (1988)

[6]

Panici P.B., Scambia G., Baiocchi G., Et al., Circulating tumor markers in cervical cancer, Tumor Biol, 10, pp. 109-116, (1989)

[7]

McGuckin M.A., Ramm L.E., Joy G.J., Free K.E., Ward B.G., Preoperative discrimination between ovarian carcinoma, non-ovarian gynecologic malignancy and benign adnexal masses using serum levels of CA125 and the polymorphic epithelial mucin antigens CASA, OSA, and MSA, Int/Gynecol Cancer, 2, pp. 119-128, (1992)

[8]

McGuckin M.A., Layton G.T., Bailey M.J., Khoo S.K., Hurst T., Ward B.G., Evaluation of two new assays for tumour- associated antigen, CASA and OSA, found in the serum of patients with epithelial ovarian carcinoma—comparison to CA125, Gynec Oncol, 37, pp. 165-171, (1990)

[9]

Ward B.G., McGuckin M.A., Ramm L.E., Et al., The management of ovarian carcinoma is improved by the use of cancer- associated serum antigen (CASA) and CA125 assays, Cancer, 71, pp. 430-438, (1993)

[10]

Van Dalen A., Favier J., CA125 and TPS in the Management of Ovarian Cancer Patients. Presented At: CA125—Ten Years Later, (1993)

← 1 2 3 →